Paul-Ehrlich-Institut

Coronavirus and COVID-19

Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations

As of 15 January 2022, the following criteria apply to proof of vaccination as defined in the COVID-19 Protective Measures Exceptions Ordinance (SchAusnahmV) and the Coronavirus Entry Ordinance (CoronaEinreiseV).

Changes to the criteria will be posted here as soon as reasonably possible.

Pursuant to section 2 sentence 3 of the SchAusnahmV and section 2 sentence 10 of the CoronaEinreiseV, proof of complete vaccination protection against the coronavirus SARS-CoV-2 exists if the underlying vaccinations correspond to the requirements published by the Paul-Ehrlich-Institut. These requirements, published in consultation with the Robert Koch-Institut and taking currently available medical information into account, must be met with respect to the following criteria:

  • a) the vaccine used,
  • b) the number of individual vaccinations required for complete vaccination protection,
  • c) any booster vaccinations required for continued full vaccination protection,
  • d) the length of time

    • a) that must pass after vaccination for complete vaccination protection and
    • b) that must not be exceeded between individual vaccinations and booster vaccinations.

The following vaccines can be used in the following combinations for full vaccination protection.

Requirements for full vaccination protection with a vaccine

VaccineMarketing Authorisation HolderNumber of vaccine doses for complete vaccination
Comirnaty
Authorisation No. EU/1/20/1528
BioNTech Manufacturing GmbH2
Spikevax
Authorisation No. EU/1/20/1507
Moderna Biotech Spain, S.L.2
Vaxzevria
Authorisation No. EU/1/21/1529
AstraZeneca AB, Schweden2
COVID-19 Vaccine Janssen
Authorisation No. EU/1/20/1525
Janssen-Cilag International NV2

Requirements for complete vaccination protection with different vaccines (heterologous vaccination schedule)

Vaccination 1Vaccination 2Number of vaccine doses for complete vaccination
Vaxzevria
Authorisation No. EU/1/21/1529
Comirnaty
Authorisation No. EU/1/20/1528
2
Vaxzevria
Authorisation No. EU/1/21/1529
Spikevax
Authorisation No. EU/1/20/1507
2
Comirnaty
Authorisation No. EU/1/20/1528
Spikevax
Authorisation No. EU/1/20/1507
2
Spikevax
Authorisation No. EU/1/20/1507
Comirnaty
Authorisation No. EU/1/20/1528
2
COVID-19 Vaccine Janssen
Authorisation No. EU/1/20/1525
Comirnaty
Authorisation No. EU/1/20/1528
2
COVID-19 Vaccine Janssen
Authorisation No. EU/1/20/1525
Spikevax
Authorisation No. EU/1/20/1507
2

List of marketing authorisations and vaccine product names in third countries (outside the EU and EEA)

Versions of EU-authorised vaccines authorised abroad (original or licensed productions) are equivalent to the named EU-authorised vaccines as proof of vaccination protection. For more information, please refer to the list below.

Comirnaty

State / Community of States / Organisation (German notation)Product Name
AlbanienCOMIRNATY
AlgerienPfizer-BioNTech COVID-19 vaccine
ArgentinienCOMIRNATY
AustralienCOMIRNATY
BahrainPfizer-BioNTech COVID-19 vaccine
BrasilienCOMIRNATY
ChilePfizer-BioNTech COVID-19 vaccine
Costa RicaPfizer-BioNTech COVID-19 vaccine
Dominikanische RepublikPfizer-BioNTech COVID-19 vaccine
EcuadorPfizer-BioNTech COVID-19 vaccine
El SalvadorPfizer-BioNTech COVID-19 vaccine
EU (all member states)Comirnaty
GeorgienPfizer-BioNTech COVID-19 vaccine
HondurasPfizer-BioNTech COVID-19 vaccine
HongkongCOMIRNATY
IrakPfizer-BioNTech COVID-19 vaccine
IslandComirnaty
IsraelPfizer-BioNTech COVID-19 vaccine
JapanCOMIRNATY
JordanienPfizer-BioNTech COVID-19 vaccine
KanadaPfizer-BioNTech COVID-19 vaccine
KatarPfizer-BioNTech COVID-19 vaccine
KolumbienPfizer-BioNTech COVID-19 vaccine
KosovoCOMIRNATY
KuwaitPfizer-BioNTech COVID-19 vaccine
LibanonPfizer-BioNTech COVID-19 vaccine
LiechtensteinComirnaty
MacauCOMIRNATY
MalaysiaCOMIRNATY
MexikoPfizer-BioNTech COVID-19 vaccine
MoldawienCOMIRNATY
MongoleiPfizer-BioNTech COVID-19 vaccine
NeuseelandCOMIRNATY
NordmazedonienCOMIRNATY
NorwegenComirnaty
OmanPfizer-BioNTech COVID-19 vaccine
PakistanCOMIRNATY
PalästinaCOMIRNATY
PanamaPfizer-BioNTech COVID-19 vaccine
ParaguayPfizer-BioNTech COVID-19 vaccine
PeruCOMIRNATY
PhilippinenPfizer-BioNTech COVID-19 vaccine
RuandaCOMIRNATY
Saudi-ArabienPfizer-BioNTech COVID-19 vaccine
SchweizCOMIRNATY
SerbienCOMIRNATY
SingapurPfizer-BioNTech COVID-19 vaccine
Sri LankaCOMIRNATY
SüdafrikaCOMIRNATY
SüdkoreaCOMIRNATY
SwasilandCOMIRNATY
TunesienPfizer-BioNTech COVID-19 vaccine
TürkeiPfizer-BioNTech COVID-19 vaccine
UkraineCOMIRNATY
UruguayPfizer-BioNTech COVID-19 vaccine
USAPfizer-BioNTech COVID-19 vaccine
Vereinigte Arabische EmiratePfizer-BioNTech COVID-19 vaccine
Vereinigtes KönigreichPfizer-BioNTech COVID-19 vaccine,
COMIRNATY
VietnamCOMIRNATY

COVID-19 Vaccine Janssen

State / Community of States / Organisation (German notation)Product Name
Afrikanische UnionCOVID-19 Vaccine Janssen
AngolaCOVID-19 Vaccine Janssen
ÄthiopienCOVID-19 Vaccine Janssen
BahrainCOVID-19 Vaccine Janssen
BotswanaCOVID-19 Vaccine Janssen
BrasilienJanssen COVID-19 Vaccine / Vacina covid-19 (recombinante)
Cabo VerdeCOVID-19 Vaccine Janssen 
ChileCOVID-19 Vaccine Janssen
Dem. Republik KongoCOVID-19 Vaccine Janssen
EU (all member states)COVID-19 Vaccine Janssen
GambiaCOVID-19 Vaccine Janssen
GhanaCOVID-19 Vaccine Janssen
Guinea-BissauCOVID-19 Vaccine Janssen
IslandCOVID-19 Vaccine Janssen
JordanienCOVID-19 Vaccine Janssen 
KanadaJanssen COVID-19 Vaccine
KatarCOVID-19 Vaccine Janssen 
KolumbienJanssen COVID-19 Vaccine / COVID-19 Vaccine Janssen
KongoCOVID-19 Vaccine Janssen
KuwaitCOVID-19 Vaccine Janssen
LesothoCOVID-19 Vaccine Janssen
LiberiaCOVID-19 Vaccine Janssen
LibyenCOVID-19 Vaccine Janssen
LiechtensteinCOVID-19 Vaccine Janssen
MadagaskarCOVID-19 Vaccine Janssen
MalawiCOVID-19 Vaccine Janssen
MalaysiaCOVID-19 Vaccine Janssen Suspension for Injection
MaliCOVID-19 Vaccine Janssen
MexikoJanssen COVID-19 Vaccine / COVID-19 Vaccine Janssen
NamibiaCOVID-19 Vaccine Janssen
NigeriaCOVID-19 Vaccine Janssen
NorwegenCOVID-19 Vaccine Janssen
PhilippinenJanssen COVID-19 Vaccine
Republik KoreaCOVID-19 Vaccine Janssen
RuandaCOVID-19 Vaccine Janssen 
SambiaCOVID-19 Vaccine Janssen 
Sao Tome und PrincipeCOVID-19 Vaccine Janssen
Saudi-ArabienCOVID-19 Vaccine Janssen
SchweizCOVID-19 Vaccine Janssen
SenegalCOVID-19 Vaccine Janssen
SüdafrikaCOVID-19 Vaccine Janssen
ThailandCOVID-19 Vaccine Janssen / Janssen COVID-19 Vaccine
TogoCOVID-19 Vaccine Janssen
TunesienCOVID-19 Vaccine Janssen
USAJanssen COVID-19 Vaccine
Vereinigtes KönigreichCOVID-19 Vaccine Janssen
WHOCOVID-19 Vaccine Janssen
Zentralafrikanische RepublikCOVID-19 Vaccine Janssen

Spikevax (formerly: COVID-19 Vaccine Moderna)

State / Community of States / Organisation (German notation)Product Name
BotswanaCovid-19 Vaccine Moderna Dispersion for injection
BruneiModerna Covid-19 Vaccine (mRNA-1273 Vaccine)
EU (all member states)Spikevax (formerly: COVID-19 Vaccine Moderna)
IslandSpikevax (formerly: COVID-19 Vaccine Moderna)
IsraelCovid-19 Vaccine Moderna Dispersion for injection
JapanCovid-19 Vaccine Moderna Intramuscular injection
JordanienCovid-19 Vaccine Moderna
KanadaCovid-19 Vaccine Moderna Dispersion for injection
KatarCovid-19 Vaccine Moderna Dispersion for injection
LiechtensteinSpikevax (formerly: COVID-19 Vaccine Moderna)
NorwegenSpikevax (formerly: COVID-19 Vaccine Moderna)
Paraguayn/a
PhilippinenCovid-19 Vaccine Moderna
SchweizCovid-19 Vaccine Moderna Dispersion for injection
SingapurCovid-19 Vaccine Moderna Dispersion for injection
SüdkoreaCovid-19 Vaccine Moderna
TaiwanModerna Covid-19 Vaccine
ThailandCovid-19 Vaccine Moderna
USAModerna Covid-19 Vaccine Suspension for injection
Vereinigtes KönigreichCovid-19 Vaccine Moderna Dispersion for injection
WHOCovid-19 Vaccine Moderna

Nuvaxovid (NVX-CoV2373)

State / Community of States / Organisation (German notation)Product Name
EU (all member states)Nuvaxovid
IndonesienCovovax
PhilippinenCovovax
WHOCovovax

Vaxzevria (formerly: COVID-19 Vaccine AstraZeneca)

State / Community of States / Organisation (German notation)Product NameCompany
ÄgyptenCovishieldSerum Institute of India (AstraZeneca licensee)
ArgentinienCovid-19 Vaccine, ASTRAZENECA ®AstraZeneca
ArgentinienCovishieldSerum Institute of India (AstraZeneca licensee)
AustralienCOVID-19 Vaccine AstraZenecaAstraZeneca
BahrainR-CoVIR-PHARM (AstraZeneca licensee)
BahrainCovishieldSerum Institute of India (AstraZeneca licensee)
BangladeshCovishieldSerum Institute of India (AstraZeneca licensee)
BotswanaCovishieldSerum Institute of India (AstraZeneca licensee)
BrasilienCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
BrasilienCovid-19 vaccine (recombinant)FUNDAÇÃO Instituto OSWALDO CRUZ (FIOCRUZ) (AstraZeneca licensee)
BrasilienCovishieldSerum Institute of India (AstraZeneca licensee)
BruneiCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
ChileCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
Costa RicaCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
Dominikanische RepublikCovid-19 Vaccine AstraZenecaAstraZeneca
Dominikanische RepublikCovishieldSerum Institute of India (AstraZeneca licensee)
Dubai (UAE)R-CoVIR-PHARM (AstraZeneca licensee)
EcuadorVacuna AstraZeneca COVID-19 / Covid-19 Vaccine AstraZenecaAstraZeneca
El SalvadorCOVID-19 Vaccine AstraZenecaAstraZeneca
El SalvadorCovishieldSerum Institute of India (AstraZeneca licensee)
EU (alle Mitgliedstaaten)Vaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)AstraZeneca
GambiaCovishieldSerum Institute of India (AstraZeneca licensee)
GhanaCovishieldSerum Institute of India (AstraZeneca licensee)
HondurasCOVID-19 Vaccine AstraZenecaAstraZeneca
IndienCovishieldSerum Institute of India (AstraZeneca licensee)
IndonesienCOVID-19 Vaccine AstraZenecaAstraZeneca
IranR-CoVIR-PHARM (AstraZeneca licensee)
IslandVaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)AstraZeneca
IsraelCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
JapanCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
JordanienR-CoVIR-PHARM (AstraZeneca licensee)
JordanienCovishieldSerum Institute of India (AstraZeneca licensee)
KanadaAstraZeneca COVID-19 Vaccine (AZD1222)
COVISHIELD Vaccine
AstraZeneca
KeniaCovishieldSerum Institute of India (AstraZeneca licensee)
KolumbienCovid-19 Vaccine AstraZeneca AstraZeneca
KuwaitR-CoVIR-PHARM (AstraZeneca licensee)
KuwaitCovishieldSerum Institute of India (AstraZeneca licensee)
LibanonR-CoVIR-PHARM (AstraZeneca licensee)
LiechtensteinVaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)AstraZeneca
MacauCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
MalaysiaCOVID-19 Vaccine AstraZenecaAstraZeneca
MaledivenCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
MaledivenCovishieldSerum Institute of India (AstraZeneca licensee)
MarokkoR-CoVIR-PHARM (AstraZeneca licensee)
MarokkoCovishieldSerum Institute of India (AstraZeneca licensee)
MexikoVacuna AstraZeneca COVID-19AstraZeneca
MongoleiR-CoVIR-PHARM (AstraZeneca licensee)
MontenegroCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
MyanmarCovishieldSerum Institute of India (AstraZeneca licensee)
NamibiaCovishieldSerum Institute of India (AstraZeneca licensee)
NauruCovishieldSerum Institute of India (AstraZeneca licensee)
NepalCovishieldSerum Institute of India (AstraZeneca licensee)
NeuseelandCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
NicaraguaCovishieldSerum Institute of India (AstraZeneca licensee)
NigeriaCovishieldSerum Institute of India (AstraZeneca licensee)
NorwegenVaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)AstraZeneca
OmanR-CoVIR-PHARM (AstraZeneca licensee)
OmanCovishieldSerum Institute of India (AstraZeneca licensee)
PakistanCovishieldSerum Institute of India (AstraZeneca licensee)
PalästinaR-CoVIR-PHARM (AstraZeneca licensee)
PalästinaCovishieldSerum Institute of India (AstraZeneca licensee)
PanamaCOVID-19 Vaccine AstraZenecaAstraZeneca
PhilippinenCOVID-19 Vaccine AstraZenecaAstraZeneca
RuandaCovishieldSerum Institute of India (AstraZeneca licensee)
Saudi-ArabienCovishieldSerum Institute of India (AstraZeneca licensee)
SchweizCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
SenegalCovishieldSerum Institute of India (AstraZeneca licensee)
SerbienCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
SingapurCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
Sri LankaCovishieldSerum Institute of India (AstraZeneca licensee)
SüdafrikaCovishieldSerum Institute of India (AstraZeneca licensee)
SüdkoreaAstraZeneca Korea COVID-19 VaccineAstraZeneca
TaiwanCOVID-19 Vaccine AstraZenecaAstraZeneca
ThailandCOVID-19 Vaccine AstraZenecaAstraZeneca
TurkmenistanR-CoVIR-PHARM (AstraZeneca licensee)
UkraineCovishieldSerum Institute of India (AstraZeneca licensee)
UkraineCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
UngarnAstra ChAdOx1 SAstraZeneca
UruguayCOVID-19 Vaccine AstraZenecaAstraZeneca
Vereinigtes KönigreichCovid-19 Vaccine AstraZeneca/VaxzevriaAstraZeneca
VietnamCOVID-19 Vaccine AstraZenecaAstraZeneca
WHOCOVID-19 Vaccine AstraZenecaAstraZeneca

WHO EUL (Emergency Use Listing)

Product NameCompany
AZD1222AstraZeneca
BNT162b2/COMIRNATY, Tozinameran (INN)BioNTech/Pfizer
Covishield (ChAdOx1_nCoV-19)Serum Institute of India (AstraZeneca licensee)
CovovaxNovavax
mRNA-1273Moderna

List of authorisations and vaccine product names in third countries (outside the EU and EEA) - As of 21 December 2021

The list is provided for informational purposes and does not claim to be complete. The person wishing to enter the country is responsible for providing proof of complete vaccination protection with a recognized, EU-authorised vaccine as defined by the Ordinance on Coronavirus Entry Regulations.

Time interval after vaccination for complete vaccination protection

Fourteen days must have passed since the last required vaccination in order for the vaccination to be considered complete.

Exceptional circumstances justifying full vaccination protection with a single dose of vaccine

Notwithstanding the requirements above, a single dose of vaccine with any of the vaccines listed above is considered sufficient if

  • the person concerned has physical or digital proof in German, English, French, Italian or Spanish of a positive antibody test carried out on them and this test was carried out at a time when the person concerned had not yet received a vaccination against COVID-19. The laboratory diagnostic findings must have come from a laboratory that works in accordance with the guidelines of the German Medical Association on Quality Assurance in Medical Laboratory Examinations (RiLiBÄK) or that is accredited in accordance with DIN EN ISO 15189. In this case, the 14-day post-vaccination period does not apply.
  • the person concerned has proof of a previous infection with the SARS-CoV-2 coronavirus. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection laboratory diagnostics (PCR, POC-PCR or other nucleic acid amplification technology methods) and this test must have been carried out at a time when the person concerned had not yet been vaccinated against COVID-19. If the infection occurred before the first vaccination was given, the required 14-day post vaccination period does not apply.
  • the person concerned was infected with the SARS-CoV-2 coronavirus after receiving a single vaccine dose. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection (PCR, POC-PCR or other nucleic acid amplification technology methods). If the infection occurred after the first vaccine dose was administered, 28 days must have passed since the infection was first detected.

Note

Information on booster vaccinations and the corresponding time intervals has not yet been published.

As of

15 January 2022

Content

  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations
  4. FAQ Coronavirus
  5. Biomedicines
  6. Safety of COVID-19 Vaccines
  7. Research Work
  8. SARS-CoV-2 Test Systems